Cancer-id
Toward identification of cancer by tumor-derived extracellular vesicles in blood
L. G. Rikkert (University of Twente, Amsterdam UMC)
P. Beekman (University of Twente, Wageningen University & Research)
J Caro (TU Delft - ImPhys/Computational Imaging)
F. A.W. Coumans (Amsterdam UMC)
A. Enciso-Martinez (University of Twente)
G. Jenster (Erasmus MC)
S. Le Gac (University of Twente)
W. Lee (University of Twente)
G. B. Loozen (TU Delft - ImPhys/Computational Imaging)
More Authors (External organisation)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Extracellular vesicles (EVs) have great potential as biomarkers since their composition and concentration in biofluids are disease state dependent and their cargo can contain disease-related information. Large tumor-derived EVs (tdEVs, >1μm) in blood from cancer patients are associated with poor outcome, and changes in their number can be used to monitor therapy effectiveness. Whereas, small tumor-derived EVs (<1μm) are likely to outnumber their larger counterparts, thereby offering better statistical significance, identification and quantification of small tdEVs are more challenging. In the blood of cancer patients, a subpopulation of EVs originate from tumor cells, but these EVs are outnumbered by non-EV particles and EVs from other origin. In the Dutch NWO Perspectief Cancer-ID program, we developed and evaluated detection and characterization techniques to distinguish EVs from non-EV particles and other EVs. Despite low signal amplitudes, we identified characteristics of these small tdEVs that may enable the enumeration of small tdEVs and extract relevant information. The insights obtained from Cancer-ID can help to explore the full potential of tdEVs in the clinic.
help_outline